Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Following cervical and uterine cancer, ovarian cancer (OC) has the third rank in gynecologic cancers. It often remains non-diagnosed until it spreads throughout the pelvis and abdomen. Identification of the most effective risk factors can help take prevention measures concerning OC. Therefore, the presented review aims to summarize the available studies on OC risk factors. A comprehensive systematic literature search was performed to identify all published systematic reviews and meta-analysis on associated factors with ovarian cancer. Web of Science, Cochrane Library databases, and Google Scholar were searched up to 17th January 2020. This study was performed according to Smith et al. methodology for conducting a systematic review of systematic reviews. Twenty-eight thousand sixty-two papers were initially retrieved from the electronic databases, among which 20,104 studies were screened. Two hundred seventy-seven articles met our inclusion criteria, 226 of which included in the meta-analysis. Most commonly reported genetic factors were MTHFR C677T (OR=1.077; 95 % CI (1.032, 1.124); P-value<0.001), BSML rs1544410 (OR=1.078; 95 %CI (1.024, 1.153); P-value=0.004), and Fokl rs2228570 (OR=1.123; 95 % CI (1.089, 1.157); P-value<0.001), which were significantly associated with increasing risk of ovarian cancer. Among the other factors, coffee intake (OR=1.106; 95 % CI (1.009, 1.211); P-value=0.030), hormone therapy (RR=1.057; 95 % CI (1.030, 1.400); P-value<0.001), hysterectomy (OR=0.863; 95 % CI (0.745, 0.999); P-value=0.049), and breast feeding (OR=0.719, 95 % CI (0.679, 0.762) and P-value<0.001) were mostly reported in studies. Among nutritional factors, coffee, egg, and fat intake significantly increase the risk of ovarian cancer. Estrogen, estrogen-progesterone, and overall hormone therapies also are related to the higher incidence of ovarian cancer. Some diseases, such as diabetes, endometriosis, and polycystic ovarian syndrome, as well as several genetic polymorphisms, cause a significant increase in ovarian cancer occurrence. Moreover, other factors, for instance, obesity, overweight, smoking, and perineal talc use, significantly increase the risk of ovarian cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582179PMC
http://dx.doi.org/10.1186/s13048-021-00911-zDOI Listing

Publication Analysis

Top Keywords

ovarian cancer
12
review systematic
8
systematic review
8
risk factors
8
systematic reviews
8
systematic
5
investigation factors
4
factors associated
4
associated ovarian
4
cancer
4

Similar Publications

Background: Local control strategies in pediatric oncology are guided by disease-specific considerations. Effective communication of the goals of surgical procedure and associated intraoperative events plays a crucial role in shaping subsequent treatment decisions. However, accurately and comprehensively documenting these findings remains challenging, with considerable variability across different tumor types.

View Article and Find Full Text PDF

We previously screened a peptide PDBAG1 that remarkably inhibited triple-negative breast cancer, and found that its target was C1QBP. Recently, C1QBP has been reported as a potential tumor marker in ovarian cancer, which of the mortality rate ranks first among malignant tumors of the female reproductive tract. However, it is unclear whether and how PDBAG1 plays a regulatory role in ovarian cancer.

View Article and Find Full Text PDF

Platinum-group metal half-sandwich complexes are considered to be potential replacements of the clinically widely used platins which have several side effects and tend to cause resistance to develop. In our previous works, we used a range of 2-pyridyl-substituted N- and C-glycosyl heterocycles as N,N-chelating ligands to prepare ruthenium(II), osmium(II), iridium(III) and rhodium(III) polyhapto arene/arenyl half-sandwich complexes. Some of these complexes, particularly with the C-glucopyranosyl isoxazole derived ligand in its O-perbenzoylated form, exhibited greater anticancer efficiency than cisplatin and had minimal or negligible effects on non-transformed fibroblasts.

View Article and Find Full Text PDF

GJB2 promotes ovarian cancer progression and cisplatin resistance by upregulating TNC expression.

Biochim Biophys Acta Mol Cell Res

September 2025

Department of Clinical Laboratory, North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital-Tangshan, China; Key Laboratory of Molecular Medicine for Abnormal Development and Related Diseases in Tangshan City-Tangshan, China. Electronic address: wu

Cisplatin resistance continues to be a major obstacle in the treatment of ovarian cancer (OC). Gap junction protein β-2 (GJB2), a key member of the connexin family, is well-known for its association with hereditary deafness. However, its role in ovarian cancer chemotherapy resistance remains unexplored.

View Article and Find Full Text PDF

Development of six novel dinuclear calcium(II) complexes based on 8-hydroxyquinoline as anticancer agents.

J Inorg Biochem

September 2025

State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Road, Guilin 541004, PR China. Electronic address:

This study reports the synthesis and antitumor evaluation of six novel dinuclear calcium(II) complexes with the general formula [Ca(μ-O)(QM)(QH)], designated as CaQ1 through CaQ6. These complexes incorporate various deprotonated 8-hydroxyquinoline ligands (H-QM-H-QM) and 1,10-phenanthroline derivatives (QH), synthesized using Ca(NO)·4HO. The specific compositions are as follows: CaQ1: H-QM = 5,7-dibromo-8-hydroxyquinoline (x = 1), QH = bathophenanthroline; CaQ2: H-QM = 5,7-dichloro-8-quinolinol (x = 2), QH = bathophenanthroline; CaQ3: H-QM = 5,7-diiodo-8-hydroxyquinoline (x = 3), QH = 1,10-phenanthroline; CaQ4: H-QM = 5,7-dichloro-8-quinolinol (x = 2), QH = 1,10-phenanthroline; CaQ5: H-QM = clioquinol (x = 4), QH = 1,10-phenanthroline; CaQ6: H-QM = 5,7-dibromo-8-hydroxyquinoline (x = 1), QH = 1,10-phenanthroline.

View Article and Find Full Text PDF